Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Hemorrhage | 32 | 2024 | 237 | 14.610 |
Why?
|
| Colonoscopy | 14 | 2023 | 279 | 4.540 |
Why?
|
| Anticoagulants | 11 | 2022 | 427 | 3.640 |
Why?
|
| Hospitalization | 11 | 2022 | 877 | 3.040 |
Why?
|
| Patient Discharge | 7 | 2024 | 320 | 2.140 |
Why?
|
| Hemostasis, Endoscopic | 3 | 2018 | 16 | 1.850 |
Why?
|
| Esophageal Diseases | 3 | 2015 | 27 | 1.520 |
Why?
|
| Warfarin | 3 | 2020 | 104 | 1.410 |
Why?
|
| Risk Assessment | 8 | 2019 | 2303 | 1.160 |
Why?
|
| Liver Cirrhosis | 4 | 2018 | 256 | 1.140 |
Why?
|
| Colonic Polyps | 4 | 2023 | 132 | 1.140 |
Why?
|
| Esophageal Neoplasms | 4 | 2018 | 332 | 1.080 |
Why?
|
| Fibrinolytic Agents | 2 | 2018 | 217 | 1.060 |
Why?
|
| Humans | 63 | 2024 | 89357 | 1.050 |
Why?
|
| Esophageal Stenosis | 2 | 2015 | 26 | 1.020 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2015 | 18 | 1.010 |
Why?
|
| Endoscopy, Digestive System | 2 | 2015 | 68 | 1.000 |
Why?
|
| Patient Readmission | 3 | 2019 | 352 | 0.980 |
Why?
|
| Liver Diseases | 2 | 2017 | 242 | 0.970 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2023 | 157 | 0.970 |
Why?
|
| Physicians, Family | 1 | 2024 | 39 | 0.960 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 981 | 0.940 |
Why?
|
| Proton Pump Inhibitors | 2 | 2022 | 34 | 0.910 |
Why?
|
| Emergency Service, Hospital | 5 | 2024 | 521 | 0.900 |
Why?
|
| Juniperus | 1 | 2023 | 1 | 0.900 |
Why?
|
| Polyps | 1 | 2023 | 29 | 0.870 |
Why?
|
| Endoscopy | 4 | 2019 | 350 | 0.860 |
Why?
|
| Middle Aged | 31 | 2021 | 25974 | 0.830 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1047 | 0.820 |
Why?
|
| Aged | 26 | 2021 | 19165 | 0.820 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2020 | 580 | 0.820 |
Why?
|
| Propensity Score | 3 | 2021 | 147 | 0.800 |
Why?
|
| Gastroenterology | 3 | 2023 | 144 | 0.790 |
Why?
|
| Text Messaging | 1 | 2022 | 31 | 0.780 |
Why?
|
| Radiology | 1 | 2024 | 201 | 0.770 |
Why?
|
| Early Diagnosis | 2 | 2018 | 125 | 0.760 |
Why?
|
| Retrospective Studies | 16 | 2024 | 9057 | 0.750 |
Why?
|
| Blood Coagulation Factors | 1 | 2021 | 20 | 0.750 |
Why?
|
| Blood Transfusion | 2 | 2018 | 169 | 0.750 |
Why?
|
| Barrett Esophagus | 3 | 2018 | 93 | 0.740 |
Why?
|
| Vitamin K | 1 | 2021 | 25 | 0.740 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 30 | 0.730 |
Why?
|
| Risk Adjustment | 1 | 2020 | 38 | 0.710 |
Why?
|
| Patient Admission | 2 | 2018 | 114 | 0.710 |
Why?
|
| Recurrence | 7 | 2018 | 1144 | 0.700 |
Why?
|
| Thromboembolism | 2 | 2018 | 120 | 0.700 |
Why?
|
| Machine Learning | 2 | 2019 | 258 | 0.690 |
Why?
|
| Angiodysplasia | 1 | 2019 | 4 | 0.690 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 143 | 0.680 |
Why?
|
| Spiders | 1 | 2019 | 16 | 0.680 |
Why?
|
| Critical Pathways | 1 | 2019 | 37 | 0.680 |
Why?
|
| Gastrointestinal Agents | 2 | 2022 | 172 | 0.670 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 66 | 0.670 |
Why?
|
| Diverticulum, Colon | 1 | 2018 | 10 | 0.640 |
Why?
|
| Diverticulum | 1 | 2019 | 45 | 0.640 |
Why?
|
| Male | 29 | 2021 | 42411 | 0.630 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 1840 | 0.600 |
Why?
|
| Acute Disease | 4 | 2022 | 841 | 0.600 |
Why?
|
| Female | 29 | 2021 | 46202 | 0.590 |
Why?
|
| Time Factors | 5 | 2018 | 5338 | 0.590 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 159 | 0.590 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 461 | 0.580 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 19 | 0.570 |
Why?
|
| Colonic Diseases | 1 | 2017 | 61 | 0.550 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 72 | 0.550 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 75 | 0.550 |
Why?
|
| Risk Factors | 8 | 2019 | 5499 | 0.550 |
Why?
|
| Gastroenterologists | 1 | 2017 | 31 | 0.550 |
Why?
|
| Patient Care Management | 1 | 2016 | 30 | 0.550 |
Why?
|
| Aged, 80 and over | 12 | 2019 | 6811 | 0.550 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 122 | 0.540 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2016 | 175 | 0.520 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 358 | 0.520 |
Why?
|
| Stomach Diseases | 1 | 2015 | 19 | 0.520 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.510 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 167 | 0.500 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.500 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.500 |
Why?
|
| Cryosurgery | 1 | 2015 | 54 | 0.490 |
Why?
|
| Withholding Treatment | 2 | 2014 | 117 | 0.490 |
Why?
|
| Accidental Falls | 1 | 2015 | 51 | 0.490 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 79 | 0.480 |
Why?
|
| Cohort Studies | 6 | 2020 | 2872 | 0.480 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 969 | 0.470 |
Why?
|
| Physicians, Primary Care | 1 | 2016 | 105 | 0.470 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 78 | 0.470 |
Why?
|
| Hospital Mortality | 1 | 2017 | 387 | 0.470 |
Why?
|
| Multivariate Analysis | 5 | 2020 | 988 | 0.460 |
Why?
|
| Salvage Therapy | 1 | 2015 | 236 | 0.460 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 282 | 0.440 |
Why?
|
| Adult | 18 | 2021 | 26607 | 0.440 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 182 | 0.440 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 362 | 0.430 |
Why?
|
| Prospective Studies | 10 | 2021 | 4289 | 0.430 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 393 | 0.420 |
Why?
|
| Prognosis | 6 | 2018 | 3783 | 0.400 |
Why?
|
| Esophagoscopy | 3 | 2018 | 90 | 0.400 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 228 | 0.400 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 259 | 0.400 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 253 | 0.400 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1194 | 0.390 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3666 | 0.370 |
Why?
|
| United States | 8 | 2024 | 6989 | 0.370 |
Why?
|
| Logistic Models | 3 | 2020 | 1213 | 0.370 |
Why?
|
| Databases, Factual | 3 | 2019 | 856 | 0.360 |
Why?
|
| Glottis | 1 | 2010 | 11 | 0.350 |
Why?
|
| Vocal Cords | 1 | 2010 | 28 | 0.350 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2023 | 333 | 0.340 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 53 | 0.340 |
Why?
|
| Laryngeal Neoplasms | 1 | 2010 | 89 | 0.330 |
Why?
|
| Catheter Ablation | 3 | 2016 | 253 | 0.330 |
Why?
|
| Dabigatran | 2 | 2020 | 25 | 0.310 |
Why?
|
| Young Adult | 6 | 2020 | 6312 | 0.300 |
Why?
|
| Treatment Outcome | 6 | 2021 | 8241 | 0.300 |
Why?
|
| Administration, Oral | 2 | 2020 | 682 | 0.300 |
Why?
|
| Chickenpox | 1 | 2007 | 39 | 0.300 |
Why?
|
| Herpesvirus 3, Human | 1 | 2007 | 41 | 0.290 |
Why?
|
| Molecular Epidemiology | 1 | 2007 | 53 | 0.290 |
Why?
|
| Cryotherapy | 2 | 2018 | 30 | 0.290 |
Why?
|
| Herpes Zoster | 1 | 2007 | 79 | 0.280 |
Why?
|
| Liver | 3 | 2016 | 1208 | 0.280 |
Why?
|
| Adolescent | 7 | 2021 | 9263 | 0.280 |
Why?
|
| Diagnostic Imaging | 2 | 2023 | 479 | 0.270 |
Why?
|
| Inpatients | 2 | 2022 | 310 | 0.270 |
Why?
|
| Ceruloplasmin | 2 | 2015 | 8 | 0.260 |
Why?
|
| Hepatolenticular Degeneration | 2 | 2015 | 19 | 0.260 |
Why?
|
| Stroke | 1 | 2014 | 986 | 0.260 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 56 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 851 | 0.250 |
Why?
|
| Length of Stay | 2 | 2018 | 736 | 0.240 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2015 | 105 | 0.240 |
Why?
|
| Canada | 1 | 2024 | 208 | 0.230 |
Why?
|
| Catheters | 1 | 2024 | 76 | 0.220 |
Why?
|
| Aftercare | 1 | 2024 | 87 | 0.220 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2023 | 18 | 0.220 |
Why?
|
| Angiography | 1 | 2024 | 208 | 0.220 |
Why?
|
| Computers | 1 | 2023 | 112 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2661 | 0.220 |
Why?
|
| Crohn Disease | 2 | 2021 | 762 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 1096 | 0.210 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 15 | 0.210 |
Why?
|
| Algorithms | 2 | 2023 | 1877 | 0.200 |
Why?
|
| Cathartics | 1 | 2022 | 27 | 0.200 |
Why?
|
| Remission Induction | 2 | 2021 | 740 | 0.200 |
Why?
|
| Musculoskeletal Pain | 1 | 2021 | 10 | 0.190 |
Why?
|
| Consensus | 1 | 2023 | 356 | 0.190 |
Why?
|
| Adenoma | 2 | 2021 | 246 | 0.190 |
Why?
|
| Capsule Endoscopy | 1 | 2021 | 33 | 0.190 |
Why?
|
| Ticlopidine | 1 | 2021 | 25 | 0.190 |
Why?
|
| Aspirin | 2 | 2022 | 159 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2017 | 784 | 0.180 |
Why?
|
| Ontario | 1 | 2020 | 51 | 0.180 |
Why?
|
| Infant | 4 | 2018 | 3160 | 0.180 |
Why?
|
| Chemoprevention | 1 | 2020 | 92 | 0.180 |
Why?
|
| Child, Preschool | 4 | 2018 | 3731 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 92 | 0.170 |
Why?
|
| Artificial Intelligence | 2 | 2021 | 322 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 838 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2023 | 575 | 0.170 |
Why?
|
| Risk | 2 | 2018 | 657 | 0.170 |
Why?
|
| Incidence | 3 | 2018 | 1595 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 149 | 0.160 |
Why?
|
| Triage | 1 | 2019 | 111 | 0.160 |
Why?
|
| Data Warehousing | 1 | 2018 | 4 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2021 | 162 | 0.160 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 8 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 155 | 0.160 |
Why?
|
| Age Factors | 3 | 2018 | 1870 | 0.160 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 32 | 0.160 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2019 | 67 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2018 | 337 | 0.150 |
Why?
|
| Hepatic Encephalopathy | 1 | 2018 | 39 | 0.150 |
Why?
|
| Data Mining | 1 | 2018 | 43 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2022 | 451 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2018 | 70 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 416 | 0.150 |
Why?
|
| Nitrogen | 1 | 2018 | 73 | 0.150 |
Why?
|
| Secondary Prevention | 1 | 2018 | 158 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.140 |
Why?
|
| Comorbidity | 2 | 2018 | 949 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1723 | 0.140 |
Why?
|
| Models, Educational | 1 | 2017 | 49 | 0.140 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2016 | 12 | 0.140 |
Why?
|
| Disease Progression | 2 | 2018 | 1489 | 0.140 |
Why?
|
| Fecal Impaction | 1 | 2016 | 3 | 0.140 |
Why?
|
| Liver Function Tests | 1 | 2016 | 92 | 0.140 |
Why?
|
| Gastroscopy | 1 | 2016 | 25 | 0.140 |
Why?
|
| Hospital Charges | 1 | 2016 | 29 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 895 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 683 | 0.140 |
Why?
|
| Program Development | 1 | 2017 | 123 | 0.140 |
Why?
|
| Emergencies | 1 | 2017 | 121 | 0.140 |
Why?
|
| Mentors | 1 | 2017 | 87 | 0.130 |
Why?
|
| Pyridines | 1 | 2018 | 315 | 0.130 |
Why?
|
| Child | 4 | 2018 | 7174 | 0.130 |
Why?
|
| Medicare | 2 | 2016 | 425 | 0.130 |
Why?
|
| Hepatitis | 1 | 2015 | 34 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 307 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2015 | 25 | 0.130 |
Why?
|
| Medical Overuse | 1 | 2015 | 36 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 51 | 0.120 |
Why?
|
| beta-Alanine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Colonic Pouches | 1 | 2015 | 68 | 0.120 |
Why?
|
| Rivaroxaban | 1 | 2014 | 12 | 0.120 |
Why?
|
| Enoxaparin | 1 | 2014 | 23 | 0.120 |
Why?
|
| Thiophenes | 1 | 2014 | 43 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 2015 | 67 | 0.120 |
Why?
|
| Nucleosides | 1 | 2014 | 22 | 0.120 |
Why?
|
| Morpholines | 1 | 2014 | 69 | 0.120 |
Why?
|
| Food | 1 | 2015 | 90 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2015 | 216 | 0.120 |
Why?
|
| Pyridones | 1 | 2014 | 56 | 0.120 |
Why?
|
| Eosinophils | 1 | 2015 | 194 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2015 | 287 | 0.120 |
Why?
|
| Constipation | 1 | 2015 | 63 | 0.120 |
Why?
|
| Hepatitis B, Chronic | 1 | 2014 | 32 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 781 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2015 | 109 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2015 | 147 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 773 | 0.120 |
Why?
|
| Nucleotides | 1 | 2014 | 97 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2014 | 111 | 0.110 |
Why?
|
| Heparin | 1 | 2014 | 185 | 0.110 |
Why?
|
| Anesthesia | 1 | 2016 | 170 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2014 | 150 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2015 | 230 | 0.110 |
Why?
|
| Ischemia | 1 | 2015 | 251 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2016 | 341 | 0.110 |
Why?
|
| Curriculum | 1 | 2017 | 568 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 533 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2015 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2016 | 1097 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 645 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1072 | 0.090 |
Why?
|
| Mass Screening | 1 | 2015 | 636 | 0.090 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 739 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 478 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2758 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 188 | 0.090 |
Why?
|
| Prevalence | 2 | 2018 | 1243 | 0.080 |
Why?
|
| London | 1 | 2007 | 16 | 0.070 |
Why?
|
| Chickenpox Vaccine | 1 | 2007 | 7 | 0.070 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2007 | 31 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2007 | 262 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 1901 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 922 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 2018 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1365 | 0.050 |
Why?
|
| Iodine | 1 | 2023 | 43 | 0.050 |
Why?
|
| Genotype | 1 | 2007 | 1849 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 49 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 150 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2023 | 299 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2007 | 2486 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2021 | 47 | 0.050 |
Why?
|
| Ustekinumab | 1 | 2021 | 51 | 0.050 |
Why?
|
| Infliximab | 1 | 2021 | 159 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 242 | 0.040 |
Why?
|
| Animals | 1 | 2019 | 27371 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 2401 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 171 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 200 | 0.040 |
Why?
|
| Veterans | 1 | 2018 | 84 | 0.040 |
Why?
|
| Vibration | 1 | 2015 | 50 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2014 | 7 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 142 | 0.030 |
Why?
|
| Lamivudine | 1 | 2014 | 13 | 0.030 |
Why?
|
| Tenofovir | 1 | 2014 | 9 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 69 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 160 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 590 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2014 | 50 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1534 | 0.030 |
Why?
|
| Adenine | 1 | 2014 | 88 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 207 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 385 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 1184 | 0.020 |
Why?
|